within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD17_MetforminAndAcarbose;
model MetforminAndAcarbose 
   extends Pharmacolibrary.Drugs.ATC.A.A10BD17;

  annotation(Documentation(
    info ="<html><body><p>Metformin and acarbose is a combination drug used in the management of type 2 diabetes mellitus, particularly to improve glycemic control when monotherapy is insufficient. Metformin decreases hepatic glucose production and improves insulin sensitivity, while acarbose inhibits intestinal alpha-glucosidases to delay carbohydrate absorption. This fixed-dose combination is approved for use in several countries.</p><h4>Pharmacokinetics</h4><p>No publication was found reporting combined pharmacokinetic parameters for metformin and acarbose as a fixed-dose combination in humans. Individual PK profiles are known: metformin is commonly described by a one-compartment oral model with rapid absorption, while acarbose has minimal systemic absorption. The following estimates are provided based on published data for individual drugs in adult type 2 diabetic patients under oral administration.</p><h4>References</h4><ol><li><p>Fernandez, E, et al., &amp; Salmon, AB (2019). Evaluation of the pharmacokinetics of metformin and acarbose in the common marmoset. <i>Pathobiology of aging &amp; age related diseases</i> 9(1) 1657756–None. DOI:<a href=&quot;https://doi.org/10.1080/20010001.2019.1657756&quot;>10.1080/20010001.2019.1657756</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31497263/&quot;>https://pubmed.ncbi.nlm.nih.gov/31497263</a></p></li><li><p>Tiwari, R, et al., &amp; Tiwari, G (2014). Bilayer Tablet Formulation of Metformin HCl and Acarbose: A Novel Approach To Control Diabetes. <i>PDA journal of pharmaceutical science and technology</i> 68(2) 138–152. DOI:<a href=&quot;https://doi.org/10.5731/pdajpst.2014.00953&quot;>10.5731/pdajpst.2014.00953</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24668601/&quot;>https://pubmed.ncbi.nlm.nih.gov/24668601</a></p></li><li><p>Kim, S, et al., &amp; Wang, Y (2014). Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects. <i>Journal of clinical pharmacy and therapeutics</i> 39(4) 424–431. DOI:<a href=&quot;https://doi.org/10.1111/jcpt.12166&quot;>10.1111/jcpt.12166</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24806030/&quot;>https://pubmed.ncbi.nlm.nih.gov/24806030</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end MetforminAndAcarbose;
